Evidence map›Paper›PMID 32959149›Full record

ArticleEuropean journal of epidemiology2020

Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.

Francesmary Modugno, Zhuxuan Fu, Susan J Jordan, Aocs Group, Jenny Chang-Claude, Renée T Fortner, Marc T Goodman, Kirsten B Moysich, Joellen M Schildkraut, Andrew Berchuck and 13 more

Open access · greenAbstract read
In one paragraph

Article in European journal of epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. What is new about ovarian malignancies?Contemporary oncology (Poznan, Poland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 17 institutions in 5 countries.

Francesmary ModugnoWomens Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, 15213, USA. modugnof@upmc.edu.ORCID http://orcid.org/0000-0003-0637-1534
Zhuxuan FuDepartment of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 15213, USA.
Susan J JordanSchool of Public Health, University of Queensland, Herston, QLD, Australia.
Aocs GroupPopulation Health Department, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Marc T GoodmanCancer Prevention and Genetics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Kirsten B MoysichDivision of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
Joellen M SchildkrautDepartment of Public Health Sciences, University of Virginia, Box 800717, Charlottesville, VA, 22908, USA.
Andrew BerchuckDepartment of Gynecologic Oncology, Duke University Medical Center, DUMC 3079, Durham, NC, 27710, USA.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08903, USA.
Bo QinCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08903, USA.
Rebecca SutphenEpidemiology Center, College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
John R McLaughlinPublic Health Ontario, Samuel Lunenfeld Research Institute, Toronto, ON, M5T3L9, Canada.
Usha MenonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, WC1V 6LJ, UK.
Susan J RamusFaculty of Medicine, School of Women's and Children's Health, University of NSW Sydney, Sydney, NSW, 2052, Australia.
Simon A GaytherCenter for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Aleksandra Gentry-MaharajMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, WC1V 6LJ, UK.
Chloe KarpinskyjMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, WC1V 6LJ, UK.
Celeste L PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, 48109, USA.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.
Harvey A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, 06510, USA.
Penelope M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.
MRC Clinical Trials Unit at UCL · GBCedars-Sinai Medical Center · USRutgers, The State University of New Jersey · USUniversity of Pittsburgh · USUniversity of Southern California · USCancer Institute of New South Wales · AUDuke Medical Center · USGerman Cancer Research Center · DELunenfeld-Tanenbaum Research Institute · CAQIMR Berghofer Medical Research Institute · AURoswell Park Comprehensive Cancer Center · USThe University of Queensland · AUThe University of Sydney · AUUniversität Hamburg · DEUniversity of South Florida · USUniversity of Virginia · USYale University · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DEAPEN, DENNIS M. · 1985 to 2009
$18.2M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Population-Based Analysis of Ovarian Cancer BiomarkersR01CA106414 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI SUTPHEN, REBECCA · 2005 to 2009
$3.0M
Regulatory T Cell Function in Ovarian CancerR01CA126841 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2009 to 2013
$3.0M
Inflammation and Ovarian CancerR01CA095023 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUNKER, CLAREANN H. · 2003 to 2008
$2.7M
ESTROGEN, DIET, GENETICS AND ENDOMETRIAL CANCERR01CA083918 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI OLSON, SARA H · 2001 to 2005
$2.5M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
CASE CONTROL STUDY OF OVARIAN CANCER HORMONAL ETIOLOGYR01CA074850 · NCI · YALE UNIVERSITY · PI RISCH, HARVEY A · 1997 to 2002
$965k
American Cancer Society CRTG-00-196-01-CCECalifornia Cancer Research Program 00-01389V-20170, 2II0200Cancer Council NSW 191. 211 and 182Division of Cancer Epidemiology and Genetics, National Cancer Institute R01-CA074850; R01-CA080742);DOD Peer Reviewed Cancer Research Program DAMD17-02-1-0669DOD Peer Reviewed Cancer Research Program DAMD17-98-1-8659German Federal Ministry of Education and Research 01 GB 9401Medical Research and Materiel Command DAMD17-01-1- 104 0729Medical Research Council MC_UU_12023/20MRF MR_UU_12023National Health & Medical Research Council of Australia 199600, 400413 and 105 400281National Health Research and Development Program, Health Canada 6613-1415-53NCI NIH HHS K07 CA080668NCI NIH HHS K07-CA080668,R01-CA95023, MO1-RR000056 R01-CA126841NCI NIH HHS K07 CA095666NCI NIH HHS K22 CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, P30CA072720NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA063682NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA080742NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA106414NCI NIH HHS R01 CA126841NCI NIH HHS R03 CA092776NCI NIH HHS R03 CA110797NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R03 CA115214NCI NIH HHS R13 CA110770NCI NIH HHS R21 CA095113NCRR NIH HHS M01 RR000056NIH HHS P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403,NIH HHS R01 CA063678 and R01 CA063682NIH HHS R01-CA074850; R01-CA080742NIH HHS R01-CA106414-A2NIH HHS R01-CA58598, N01-CN-55424 and N01-PC-67001NIH HHS R01-CA76016Ovarian Cancer Research Fund PPD/RPCI.07Peter MacCallum Cancer Centre AOCS
6 · The paper itself

Abstract

While childbearing protects against risk of epithelial ovarian cancer (EOC), few studies have explored the impact on maternal EOC risk of sex of offspring, which may affect the maternal environment during pregnancy. We performed a pooled analysis among parous participants from 12 case-controls studies comprising 6872 EOC patients and 9101 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable logistic regression for case-control associations and polytomous logistic regression for histotype-specific associations, all adjusted for potential confounders. In general, no associations were found between offspring sex and EOC risk. However, compared to bearing only female offspring, bearing one or more male offspring was associated with increased risk of mucinous EOC (OR = 1.45; 95% CI = 1.01-2.07), which appeared to be limited to women reporting menarche before age 13 compared to later menarche (OR = 1.71 vs 0.99; P-interaction = 0.02). Bearing increasing numbers of male offspring was associated with greater risks of mucinous tumors (OR = 1.31, 1.84, 2.31, for 1, 2 and 3 or more male offspring, respectively; trend-p = 0.005). Stratifying by hormonally-associated conditions suggested that compared to bearing all female offspring, bearing a male offspring was associated with lower risk of endometrioid cancer among women with a history of adult acne, hirsutism, or polycystic ovary syndrome (OR = 0.49, 95% CI = 0.28-0.83) but with higher risk among women without any of those conditions (OR = 1.64 95% CI = 1.14-2.34; P-interaction = 0.003). Offspring sex influences the childbearing-EOC risk relationship for specific histotypes and conditions. These findings support the differing etiologic origins of EOC histotypes and highlight the importance of EOC histotype-specific epidemiologic studies. These findings also suggest the need to better understand how pregnancy affects EOC risk.

Indexed as

AdultCarcinoma, Ovarian EpithelialEndometriosisFemaleGender IdentityHumansInfant, NewbornMaleMiddle AgedOvarian NeoplasmsPregnancyCase–control studyEndometrioid ovarian cancerEpithelial ovarian cancerMucinous ovarian cancerOffspring sexPooled analysis

Identifiers

PMID32959149
PMCPMC7981786
OpenAlexW3087172083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.